Oncology Data Advisor
CME | MOC | NCPD | ILNA

Expert Guidance on the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer

0.5 CME | 0.5 NCPD | MOC | ILNA

This episode of Oncology Data Advisor TM focuses on the role of acquired resistance mutations in first-line treatment selection, the potential for central nervous system (CNS) disease, and the efficacy and safety of novel treatment options for patients with ALK-positive advanced NSCLC.

Copyright © 2021 i3 Health. All rights reserved.